• linkedin
  • Increase Font
  • Sharebar

    ALG-1001: Turning off the machinery of angiogenesis


    Clearing the VEGF burden

    “Bevacizumab pretreatment helps clear the initial VEGF burden,” Dr. Boyer explained. “ALG-1001 turns off VEGF production, angiogenesis, and reduces inflammation. Adding 1 bevacizumab pre-treatment in the stage 2 study improved the BCVA achieved with 1.0 mg of ALG-1001 by about 40%, compared to the 1.0-mg dose of ALG-1001 without bevacizumab pre-treatment in the stage 1 study. In the two combination arms, no increased efficacy over monthly bevacizumab was seen.”

    Dr. Boyer believes that these results are promising. “An important consideration is that ALG-1001 might be efficacious for the 50% of the patients with DME who have not had an adequate respond to repeated anti-VEGF treatments alone,” he added.


    David Boyer, MD

    E: [email protected]

    This article is based on a presentation Dr. Boyer delivered at the 2017 American Society of Retina Specialists meeting. Dr. Boyer is a consultant to Allegro Ophthalmics and a member of the company’s Scientific Advisory Board. ALG-1001 currently is investigational and not approved by the FDA for use in the United States.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';